Inclusion Criteria:  Patients 18 years or older. Patients with AML (de novo or secondary to MDS or previous treatment) who meet the diagnostic criteria according to WHO 2016 classification. Signature of the form consent for participation in the study.  Exclusion Criteria:  Men and women, <18 or >70 years of age. Patients with chronic myeloid leukemia blast crisis or transformation to acute leukemia of other myeloproliferative syndromes. Patients with relapsed AML. Acute promyelocytic leukemia t(15; 17) or variants. Absence of written informed consent. Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3 that is not due to the disease that motivates the treatment (AML). Transplant Comorbidity Index (HCT-CI) >3. Left ventricular ejection fraction < 40% by echocardiogram (Simpsom). Bilirubin, alkaline phosphatase or alanine aminotransferase > 3 times the upper normal limit not due to AML. Serum creatinine ≥ 2.5 mg/dL not due to AML. Positive pregnancy test or absence of effective methods of contraception in women of childbearing age. Presence of active neoplasia other than AML whose treatment is more urgent at the discretion of the treating physicians. Presence of serious psychiatric illness. Known history of infection with human immunodeficiency virus (HIV). Active uncontrolled Hepatitis C or Active uncontrolled Hepatitis B. Any other condition, such as age or associated pathology that contraindicates treatment with intensive chemotherapy, especially with anthracyclines. Any patient who does not meet the inclusion and exclusion criteria for treatment with intensive chemotherapy may be evaluated on an individual basis if it is considered that they could still benefit from this treatment.